{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T22:08:46Z","timestamp":1791756526248,"version":"4.3.4"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.metabol.2017.06.001","type":"journal-article","created":{"date-parts":[[2017,6,8]],"date-time":"2017-06-08T22:45:23Z","timestamp":1496961923000},"page":"27-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":141,"special_numbering":"C","title":["Osteogenesis imperfecta \u2013 A clinical update"],"prefix":"10.1016","volume":"80","author":[{"given":"Symeon","family":"Tournis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia D.","family":"Dede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.metabol.2017.06.001_bb0005","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1399-0004.1989.tb02912.x","article-title":"Birth prevalence rates of skeletal dysplasias","volume":"35","author":"Stoll","year":"1989","journal-title":"Clin Genet"},{"issue":"8","key":"10.1016\/j.metabol.2017.06.001_bb0010","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/ejhg.2015.81","article-title":"Genetic epidemiology, prevalence, and genotype-phenotype correlations in the Swedish population with osteogenesis imperfecta","volume":"23","author":"Lindahl","year":"2015","journal-title":"Eur J Hum Genet"},{"issue":"4","key":"10.1016\/j.metabol.2017.06.001_bb0015","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1399-0004.1989.tb03198.x","article-title":"Osteogenesis imperfecta: a genetic, radiological, and epidemiological study","volume":"36","author":"Andersen","year":"1989","journal-title":"Clin Genet"},{"key":"10.1016\/j.metabol.2017.06.001_bb0020","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic heterogeneity in osteogenesis imperfecta","volume":"16","author":"Sillence","year":"1979","journal-title":"J Med Genet"},{"key":"10.1016\/j.metabol.2017.06.001_bb0025","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1007\/s00198-016-3723-3","article-title":"Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment","volume":"12","author":"Trejo","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.metabol.2017.06.001_bb0030","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(15)00728-X","article-title":"Osteogenesis imperfecta","volume":"387","author":"Forlino","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2017.06.001_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2017.02.004","article-title":"Genetic causes and mechanisms of osteogenesis imperfecta","author":"Lim","year":"2017","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.metabol.2017.06.001_bb0040","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/ng1968","article-title":"Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal\/severe osteogenesis imperfecta","volume":"39","author":"Cabral","year":"2007","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.metabol.2017.06.001_bb0045","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cell.2006.08.039","article-title":"CRTAP is required for prolyl 3-hydroxylation and mutations cause recessive osteogenesis imperfecta","volume":"127","author":"Morello","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.metabol.2017.06.001_bb0050","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1056\/NEJMoa063804","article-title":"Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta","volume":"355","author":"Barnes","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2017.06.001_bb0055","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ajhg.2009.09.001","article-title":"PPIB mutations cause severe osteogenesis imperfecta","volume":"85","author":"vanDijk","year":"2009","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.metabol.2017.06.001_bb0060","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/humu.21647","article-title":"Identification of a mutation causing deficient BMP1m\/mTLD proteolytic activity in autosomal recessive osteogenesis imperfecta","volume":"33","author":"Martinez-Glez","year":"2012","journal-title":"Hum Mutat"},{"key":"10.1016\/j.metabol.2017.06.001_bb0065","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ajhg.2012.02.026","article-title":"Attenuated BMP1 function compromises osteogenesis, leading to bone fragility in humans and zebrafish","volume":"90","author":"Asharani","year":"2012","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.metabol.2017.06.001_bb0070","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ajhg.2010.01.034","article-title":"Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta","volume":"86","author":"Christiansen","year":"2010","journal-title":"Am J Hum Genet"},{"issue":"4","key":"10.1016\/j.metabol.2017.06.001_bb0075","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00198-016-3866-2","article-title":"Novel mutations in the SEC24D gene in Chinese families with autosomal recessive osteogenesis imperfecta","volume":"28","author":"Zhang","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.metabol.2017.06.001_bb0080","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ajhg.2015.01.002","article-title":"Mutations in SEC24D, encoding a component of the COPII machinery, cause a syndromic form of osteogenesis imperfecta","volume":"96","author":"Garbes","year":"2015","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.metabol.2017.06.001_bb0085","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/1750-1172-8-154","article-title":"Deficiency for the ER-stress transducer OASIS causes severe recessive osteogenesis imperfecta in humans","volume":"8","author":"Symoens","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.metabol.2017.06.001_bb0090","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/humu.22133","article-title":"Mutations in PLOD2 cause autosomal-recessive connective tissue disorders within the Bruck syndrome \u2013 osteogenesis imperfecta phenotypic spectrum","volume":"33","author":"Puig-Herv\u00e1s","year":"2012","journal-title":"Hum Mutat"},{"key":"10.1016\/j.metabol.2017.06.001_bb0095","first-page":"120","article-title":"Phenotypic and molecular characterization of Bruck syndrome (osteogenesis imperfecta with contractures of the large joints) caused by a recessive mutation in PLOD2","volume":"131","author":"Ha-Vinh","year":"2004","journal-title":"Am J Med Genet"},{"issue":"3","key":"10.1016\/j.metabol.2017.06.001_bb0100","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/jbmr.250","article-title":"Mutations in FKBP10 cause recessive osteogenesis imperfecta and Bruck syndrome","volume":"26","author":"Kelley","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2017.06.001_bb0105","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1002\/humu.22139","article-title":"Absence of FKBP10 in recessive type XI OI leads to diminished collagen cross-linking and reduced collagen deposition in extracellular matrix","volume":"33","author":"Barnes","year":"2012","journal-title":"Hum Mutat"},{"key":"10.1016\/j.metabol.2017.06.001_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/hmg\/dds371","article-title":"Mutations in FKBP10, which result in Bruck syndrome and recessive forms of osteogenesis imperfecta, inhibit the hydroxylation of telopeptide lysines in bone collagen","volume":"22","author":"Schwarze","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.metabol.2017.06.001_bb0115","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ajhg.2011.01.015","article-title":"Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta","volume":"88","author":"Becker","year":"2011","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.metabol.2017.06.001_bb0120","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1002\/jbmr.487","article-title":"Mutations in SERPINF1 cause osteogenesis imperfecta type VI","volume":"26","author":"Homan","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2017.06.001_bb0125","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ajhg.2010.05.016","article-title":"Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta","volume":"87","author":"Lapunzina","year":"2010","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.metabol.2017.06.001_bb0130","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1215458","article-title":"WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta","volume":"368","author":"Laine","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2017.06.001_bb0135","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ajhg.2013.02.009","article-title":"WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta","volume":"92","author":"Pyott","year":"2013","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.metabol.2017.06.001_bb0140","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.gene.2014.05.028","article-title":"A novel deletion mutation involving TMEM38B in a patient with autosomal recessive osteogenesis imperfecta","volume":"545","author":"Rubinato","year":"2014","journal-title":"Gene"},{"key":"10.1016\/j.metabol.2017.06.001_bb0145","doi-asserted-by":"crossref","DOI":"10.1002\/humu.22274","article-title":"A deletion mutation in TMEM38B associated with autosomal recessive osteogenesis imperfecta","author":"Volodarsky","year":"2013","journal-title":"Hum Mutat"},{"key":"10.1016\/j.metabol.2017.06.001_bb0150","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ajhg.2012.06.005","article-title":"A single recurrent mutation in the 50-UTR of IFITM5 causes osteogenesis imperfecta type V","volume":"91","author":"Cho","year":"2012","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.metabol.2017.06.001_bb0155","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ajhg.2012.06.011","article-title":"A mutation in the 50-UTR of IFITM5 creates an in-frame start codon and causes autosomal dominant osteogenesis imperfecta type V with hyperplastic callus","volume":"91","author":"Semler","year":"2012","journal-title":"Am J Hum Genet"},{"issue":"6","key":"10.1016\/j.metabol.2017.06.001_bb0160","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/jbmr.1592","article-title":"Bone geometry, density, and microarchitecture in the distal radius and tibia in adults with osteogenesis imperfecta type I assessed by high-resolution pQCT","volume":"27","author":"Folkestad","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.1016\/j.metabol.2017.06.001_bb0165","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S8756-3282(00)00269-6","article-title":"Static and dynamic bone histomorphometry in children with osteogenesis imperfecta","volume":"26","author":"Rauch","year":"2000","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2017.06.001_bb0170","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bone.2014.05.022","article-title":"Reduced diaphyseal strength associated with high intracortical vascular porosity within long bones of children with osteogenesis imperfecta","volume":"66","author":"Albert","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2017.06.001_bb0175","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.bone.2014.04.030","article-title":"Mechanical and mineral properties of osteogenesis imperfecta human bones at the tissue level","volume":"65","author":"Imbert","year":"2014","journal-title":"Bone"},{"issue":"9","key":"10.1016\/j.metabol.2017.06.001_bb0180","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/jbmr.1942","article-title":"Skeletal clinical characteristics of osteogenesis imperfecta caused by haploinsufficiency mutations in COL1A1","volume":"28","author":"Ben Amor","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"26","key":"10.1016\/j.metabol.2017.06.001_bb0185","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJM198406283102602","article-title":"Osteogenesis imperfecta after the menopause","volume":"310","author":"Paterson","year":"1984","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.metabol.2017.06.001_bb0190","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ajmg.1320450207","article-title":"Natural history of blue sclerae in osteogenesis imperfecta","volume":"45","author":"Sillence","year":"1993","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.metabol.2017.06.001_bb0195","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-3-31","article-title":"Hereditary dentine disorders: dentinogenesis imperfecta and dentine dysplasia","volume":"3","author":"Barron","year":"2008","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"10.1016\/j.metabol.2017.06.001_bb0200","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1365-263X.2010.01033.x","article-title":"Dentinogenesis imperfecta in children with osteogenesis imperfecta: a clinical and ultrastructural study","volume":"20","author":"Majorana","year":"2010","journal-title":"Int J Paediatr Dent"},{"issue":"2","key":"10.1016\/j.metabol.2017.06.001_bb0205","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1079-2104(99)70272-6","article-title":"Evaluation of oral problems in an osteogenesis imperfecta population","volume":"87","author":"O'Connell","year":"1999","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"10","key":"10.1016\/j.metabol.2017.06.001_bb0210","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1177\/000348940211101014","article-title":"Hearing loss in Finnish adults with osteogenesis imperfecta: a nationwide survey","volume":"111","author":"Kuurila","year":"2002","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"2","key":"10.1016\/j.metabol.2017.06.001_bb0215","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3109\/01050398409043042","article-title":"Hearing loss in patients with osteogenesis imperfecta. A clinical and audiological study of 201 patients","volume":"13","author":"Pedersen","year":"1984","journal-title":"Scand Audiol"},{"key":"10.1016\/j.metabol.2017.06.001_bb0220","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1750-1172-6-88","article-title":"Osteogenesis Imperfecta: the audiological phenotype lacks correlation with the genotype","volume":"6","author":"Swinnen","year":"2011","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"10.1016\/j.metabol.2017.06.001_bb0225","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1007\/s00198-005-1905-5","article-title":"Musculoskeletal manifestations of mild osteogenesis imperfecta in the adult","volume":"16","author":"McKiernan","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.metabol.2017.06.001_bb0230","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/1471-2474-15-428","article-title":"Association between joint hypermobility, scoliosis, and cranial base anomalies in paediatric osteogenesis imperfecta patients: a retrospective cross-sectional study","volume":"15","author":"Arponen","year":"2014","journal-title":"BMC Musculoskelet Disord"},{"issue":"5","key":"10.1016\/j.metabol.2017.06.001_bb0235","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.apmr.2003.08.085","article-title":"Osteogenesis imperfecta in childhood: impairment and disability. A prospective study with 4-year follow-up","volume":"85","author":"Engelbert","year":"2004","journal-title":"Arch Phys Med Rehabil"},{"issue":"2","key":"10.1016\/j.metabol.2017.06.001_bb0240","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/jbmr.220","article-title":"Cranial base abnormalities in osteogenesis imperfecta: phenotypic and genotypic determinants","volume":"26","author":"Cheung","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1016\/j.metabol.2017.06.001_bb0245","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/jbmr.1555","article-title":"Prevalence and natural course of craniocervical junction anomalies during growth in patients with osteogenesis imperfecta","volume":"27","author":"Arponen","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"3","key":"10.1016\/j.metabol.2017.06.001_bb0250","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3171\/2014.11.PEDS14113","article-title":"Cranial base pathology in pediatric osteogenesis imperfecta patients treated with bisphosphonates","volume":"15","author":"Arponen","year":"2015","journal-title":"J Neurosurg Pediatr"},{"key":"10.1016\/j.metabol.2017.06.001_bb0255","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/BF02011910","article-title":"Craniocervical abnormalities in osteogenesis imperfecta: genetic and molecular correlation","volume":"24","author":"Sillence","year":"1994","journal-title":"Pediatr Radiol"},{"issue":"2","key":"10.1016\/j.metabol.2017.06.001_bb0260","doi-asserted-by":"crossref","first-page":"E356","DOI":"10.1210\/jc.2013-3209","article-title":"Muscle anatomy and dynamic muscle function in osteogenesis imperfecta type I","volume":"99","author":"Veilleux","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.metabol.2017.06.001_bb0265","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/PEP.0000000000000042","article-title":"Muscle strength, joint range of motion, and gait in children and adolescents with osteogenesis imperfecta","volume":"26","author":"Brizola","year":"2014","journal-title":"Pediatr Phys Ther"},{"key":"10.1016\/j.metabol.2017.06.001_bb0270","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ijcard.2016.09.107","article-title":"Cardiovascular disease in patients with osteogenesis imperfecta \u2013 a nationwide, register-based cohort study","volume":"225","author":"Folkestad","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.metabol.2017.06.001_bb0275","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ijcard.2015.06.001","article-title":"Heart disease in patients with osteogenesis imperfecta \u2013 a systematic review","volume":"196","author":"Ashournia","year":"2015","journal-title":"Int J Cardiol"},{"issue":"8","key":"10.1016\/j.metabol.2017.06.001_bb0280","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/jcp.49.8.627","article-title":"Causes of death in osteogenesis imperfecta","volume":"49","author":"McAllion","year":"1996","journal-title":"J Clin Pathol"},{"issue":"12","key":"10.1016\/j.metabol.2017.06.001_bb0285","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1002\/jbmr.2895","article-title":"Mortality and causes of death in patients with osteogenesis imperfecta: a register-based nationwide cohort study","volume":"31","author":"Folkestad","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"12","key":"10.1016\/j.metabol.2017.06.001_bb0290","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/ajmg.a.37365","article-title":"Nosology and classification of genetic skeletal disorders: 2015 revision","volume":"167A","author":"Bonafe","year":"2015","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.metabol.2017.06.001_bb0295","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1210\/jc.2011-1480","article-title":"Predictors and correlates of vitamin D status in children and adolescents with osteogenesis imperfecta","volume":"96","author":"Edouard","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.06.001_bb0300","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00198-015-3386-5","article-title":"Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation","volume":"27","author":"Weaver","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.metabol.2017.06.001_bb0305","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1007\/s00198-011-1868-7","article-title":"The 25(OH)D level needed to maintain a favorable bisphosphonate response is R33 ng\/ml","volume":"23","author":"Carmel","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.metabol.2017.06.001_bb0310","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bone.2012.03.026","article-title":"25 Hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis","volume":"51","author":"Peris","year":"2012","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2017.06.001_bb0315","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bone.2016.02.013","article-title":"Effect of high-dose vitamin D supplementation on bone density in youth with osteogenesis imperfecta: a randomized controlled trial","volume":"86","author":"Plante","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2017.06.001_bb0320","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s00198-016-3515-9","article-title":"The management of osteoporosis in children","volume":"27","author":"Ward","year":"2016","journal-title":"Osteoporos Int"},{"issue":"4","key":"10.1016\/j.metabol.2017.06.001_bb0325","first-page":"445","article-title":"A specialized rehabilitation approach improves mobility in children with osteogenesis imperfecta","volume":"14","author":"Hoyer-Kuhn","year":"2014","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"10.1016\/j.metabol.2017.06.001_bb0330","article-title":"The effect of whole body vibration training on bone and muscle function in children with osteogenesis imperfect","author":"H\u00f6gler","year":"2017","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.metabol.2017.06.001_bb0335","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","article-title":"Bisphosphonates: a review of their pharmacokinetic properties","volume":"18","author":"Lin","year":"1996","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2017.06.001_bb0340","first-page":"Cd005088","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","volume":"7","author":"Dwan","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.metabol.2017.06.001_bb0345","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jbmr.2410","article-title":"Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials","volume":"30","author":"Hald","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2017.06.001_bb0350","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000381713","article-title":"Efficacy and safety of bisphosphonate therapy in children with osteogenesis imperfecta: a systematic review","volume":"84","author":"Rijks","year":"2015","journal-title":"Horm Res Paediatr"},{"key":"10.1016\/j.metabol.2017.06.001_bb0355","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.bone.2006.11.020","article-title":"Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta","volume":"40","author":"Rauch","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2017.06.001_bb0360","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000355111","article-title":"Fracture during intravenous bisphosphonate treatment in a child with osteogenesis imperfecta: an argument for a more frequent, low-dose treatment regimen","volume":"81","author":"Biggin","year":"2014","journal-title":"Horm Res Paediatr"},{"key":"10.1016\/j.metabol.2017.06.001_bb0365","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/adc.86.5.356","article-title":"Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta","volume":"86","author":"Astrom","year":"2002","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.metabol.2017.06.001_bb0370","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1002\/jbmr.2567","article-title":"Intravenous bisphosphonate therapy of young children with osteogenesis imperfecta: skeletal findings during follow up throughout the growing years","volume":"30","author":"Palomo","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2017.06.001_bb0375","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S0140-6736(13)61091-0","article-title":"Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Bishop","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2017.06.001_bb0380","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1210\/jc.2010-0636","article-title":"Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study","volume":"96","author":"Ward","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.06.001_bb0385","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bone.2016.02.018","article-title":"Scoliosis in osteogenesis imperfecta caused by COL1A1\/COL1A2mutations \u2014 genotype\u2013phenotype correlations and effect of bisphosphonate treatment","volume":"86","author":"Sato","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2017.06.001_bb0390","doi-asserted-by":"crossref","first-page":"R79","DOI":"10.1530\/EJE-14-0017","article-title":"Treatment of osteogenesis imperfecta in adults","volume":"171","author":"Lindahl","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.metabol.2017.06.001_bb0395","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1210\/jc.2015-2680","article-title":"Short-term safety of zoledronic acid in young patients with bone disorders: an extensive institutional experience","volume":"100","author":"George","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.metabol.2017.06.001_bb0400","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.5037\/jomr.2013.4401","article-title":"Systematic review on the incidence of bisphosphonate related osteonecrosis of the jaw in children diagnosed with osteogenesis imperfecta","volume":"4","author":"Hennedige","year":"2013","journal-title":"J Oral Maxillofac Res"},{"key":"10.1016\/j.metabol.2017.06.001_bb0405","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bone.2016.10.004","article-title":"Timing of dental development in osteogenesis imperfecta patients with and without bisphosphonate treatment","volume":"94","author":"Vuorimies","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2017.06.001_bb0410","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/adj.12140","article-title":"The use of bisphosphonates in children: review of the literature and guidelines for dental management","volume":"59","author":"Bhatt","year":"2014","journal-title":"Aust Dent J"},{"key":"10.1016\/j.metabol.2017.06.001_bb0415","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00198-015-3331-7","article-title":"Effect of osteoporosis medications on fracture healing","volume":"27","author":"Hegde","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.metabol.2017.06.001_bb0420","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/jbmr.2486","article-title":"Osteotomy healing in children with osteogenesis imperfecta receiving bisphosphonate treatment","volume":"30","author":"Anam","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2017.06.001_bb0425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"10","key":"10.1016\/j.metabol.2017.06.001_bb0430","doi-asserted-by":"crossref","first-page":"e187","DOI":"10.4158\/EP14141.CR","article-title":"Atypical femoral fracture in an osteogenesis imperfecta patient successfully treated with teriparatide","volume":"20","author":"Holm","year":"2014","journal-title":"Endocr Pract"},{"issue":"3","key":"10.1016\/j.metabol.2017.06.001_bb0435","first-page":"278","article-title":"An atypical fracture in male patient with osteogenesis imperfecta","volume":"12","author":"Etxebarria-Foronda","year":"2015","journal-title":"Clin Cases Miner Bone Metab"},{"issue":"5","key":"10.1016\/j.metabol.2017.06.001_bb0440","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3109\/17453674.2012.729183","article-title":"Atypical femoral fracture following bisphosphonate treatment in a woman with osteogenesis imperfecta \u2013 a case report","volume":"83","author":"Meier","year":"2012","journal-title":"Acta Orthop"},{"issue":"3","key":"10.1016\/j.metabol.2017.06.001_bb0445","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1210\/jc.2012-4195","article-title":"The paradox of prevention-bilateral atypical subtrochanteric fractures due to bisphosphonates in osteogenesis imperfecta","volume":"98","author":"Manolopoulos","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.06.001_bb0450","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/BPO.0000000000000552","article-title":"Unusual femur stress fractures in children with osteogenesis imperfecta and intramedullary rods on long-term intravenous pamidronate therapy","volume":"36","author":"Hegazy","year":"2016","journal-title":"J Pediatr Orthop"},{"issue":"7","key":"10.1016\/j.metabol.2017.06.001_bb0455","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/jbmr.2805","article-title":"Recurrent proximal femur fractures in a teenager with osteogenesis imperfecta on continuous bisphosphonate therapy: are we overtreating?","volume":"31","author":"Vasanwala","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2017.06.001_bb0460","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2016-3745","article-title":"Bisphosphonate treatment and the characteristics of femoral fractures in children with osteogenesis imperfecta","author":"Vuorimies","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2017.06.001_bb0465","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/jbmr.2835","article-title":"Bone material properties in osteogenesis imperfecta","volume":"31","author":"Bishop","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2017.06.001_bb0470","first-page":"183","article-title":"First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI","volume":"12","author":"Semler","year":"2012","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"10.1016\/j.metabol.2017.06.001_bb0475","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13023-014-0145-1","article-title":"Two years' experience with denosumab for children with osteogenesis imperfecta type VI","volume":"9","author":"Hoyer-Kuhn","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.metabol.2017.06.001_bb0480","first-page":"24","article-title":"Safety and efficacy of denosumab in children with osteogenesis imperfecta \u2014 a first prospective trial","volume":"16","author":"Hoyer-Kuhn","year":"2016","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"10.1016\/j.metabol.2017.06.001_bb0485","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases","author":"Anastasilakis","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1016\/j.metabol.2017.06.001_bb0490","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s00223-013-9770-2","article-title":"Teriparatide treatment in adult patients with osteogenesis imperfecta type I","volume":"93","author":"Gatti","year":"2013","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"10.1016\/j.metabol.2017.06.001_bb0495","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1172\/JCI71101","article-title":"Evaluation of teriparatide treatment in adults with osteogenesis imperfecta","volume":"124","author":"Orwoll","year":"2014","journal-title":"J Clin Invest"},{"issue":"16","key":"10.1016\/j.metabol.2017.06.001_bb0500","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.metabol.2017.06.001_bb0505","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/jbmr.1717","article-title":"Sclerostin antibody improves skeletal parameters in a Brtl\/+ mouse model of osteogenesis imperfecta","volume":"28","author":"Sinder","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"10","key":"10.1016\/j.metabol.2017.06.001_bb0510","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/jbmr.2198","article-title":"Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta","volume":"29","author":"Jacobsen","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"8","key":"10.1016\/j.metabol.2017.06.001_bb0515","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00198-014-2737-y","article-title":"Adult Brtl\/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength","volume":"25","author":"Sinder","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.metabol.2017.06.001_bb0520","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bone.2014.06.015","article-title":"Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta","volume":"66","author":"Roschger","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2017.06.001_bb0525","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bone.2014.10.012","article-title":"Rapidly growing Brtl\/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment","volume":"71","author":"Sinder","year":"2015","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.metabol.2017.06.001_bb0530","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/jbmr.2776","article-title":"Sclerostin antibody treatment improves the bone phenotype of Crtap(\u2212\/\u2212) mice, a model of recessive osteogenesis imperfecta","volume":"31","author":"Grafe","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2017.06.001_bb0535","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.3143","article-title":"BPS804 anti-sclerostin antibody in adults with moderate osteogenesis imperfecta: results of a randomized phase 2a trial","author":"Glorieux","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"10","key":"10.1016\/j.metabol.2017.06.001_bb0540","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.metabol.2015.07.011","article-title":"Novel therapies for osteoporosis","volume":"64","author":"Makras","year":"2015","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2017.06.001_bb0550","first-page":"1","article-title":"Pharmacological and biological therapeutic strategies for osteogenesis imperfecta","volume":"9999C","author":"Marom","year":"2016","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"10.1016\/j.metabol.2017.06.001_bb0555","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"9886","key":"10.1016\/j.metabol.2017.06.001_bb0560","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049517301580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049517301580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:16:31Z","timestamp":1758428191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049517301580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":111,"alternative-id":["S0026049517301580"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2017.06.001","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osteogenesis imperfecta \u2013 A clinical update","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2017.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}